在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human Lymphocyte activation gene 3 protein(LAG3) ELISA kit

  • 中文名稱:
    人淋巴細胞活化基因3蛋白(LAG3)酶聯免疫試劑盒
  • 貨號:
    CSB-EL012719HU
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人淋巴細胞活化基因3蛋白(LAG3)酶聯免疫試劑盒(CSB-EL012719HU)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的LAG3含量。LAG3(淋巴細胞活化基因3)是一種免疫球蛋白超家族的跨膜蛋白,主要在活化的T細胞、NK細胞等免疫細胞上表達。它通過抑制T細胞活化和增殖,參與免疫調節。研究顯示,LAG3在多種腫瘤中表達,與腫瘤免疫逃逸相關,成為腫瘤免疫治療的新靶點。試劑盒檢測范圍為0.156 ng/mL-10 ng/mL,適用于腫瘤微環境研究、免疫治療藥物開發中LAG3表達動態監測、自身免疫疾病模型構建等科研場景本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    CD223 ELISA Kit; CD223 antigen ELISA Kit; FDC protein ELISA Kit; LAG-3 ELISA Kit; Lag3 ELISA Kit; LAG3_HUMAN ELISA Kit; Lymphocyte activating 3 ELISA Kit; Lymphocyte activation gene 3 ELISA Kit; Lymphocyte activation gene 3 protein ELISA Kit; Protein FDC ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    0.156 ng/mL-10 ng/mL
  • 靈敏度:
    0.039 ng/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human LAG3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
     SampleSerum(n=4)
    1:20Average %98
    Range %92-105
    1:40Average %95
    Range %87-100
    1:80Average %98
    Range %90-105
    1:160Average %94
    Range %89-99
  • 回收率:
    The recovery of human LAG3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9489-98
    EDTA plasma (n=4)9692-105
  • 標準曲線:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/mlOD1OD2AverageCorrected
    102.958 2.879 2.919 2.701
    52.469 2.374 2.422 2.204
    2.51.684 1.726 1.705 1.487
    1.251.033 1.067 1.050 0.832
    0.6250.675 0.662 0.669 0.451
    0.3120.465 0.460 0.463 0.245
    0.1560.322 0.345 0.334 0.116
    00.217 0.219 0.218  
  • 數據處理:
  • 貨期:
    3-5 working days

引用文獻

產品評價

靶點詳情

  • 功能:
    Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1. Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear.; May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
  • 基因功能參考文獻:
    1. Results demonstrated that the expression of LAG3 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. It was mainly expressed at the edge of tumor tissues suggesting that LAG3 was expressed on tumorinfiltrating lymph node cells but not in colorectal cancer cells. PMID: 30272332
    2. These results together suggested that LAG-3 is a marker of CD4(+) T cells with regulatory function; at the same time, LAG-3 might have limited the full suppressive potential of Treg cells. PMID: 29671649
    3. Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. PMID: 29520442
    4. LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs. PMID: 29045526
    5. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. PMID: 27835902
    6. Data suggest that blocking LAG3-MHC class II interactions is a potential therapeutic target in chronic lymphocytic leukemia. PMID: 28154084
    7. LAG-3 expression was correlated with expression of PD-1 on TILs and expression of PD-L1 on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 on TILs and higher expression of PD-L1 on tumor cells. PMID: 28132868
    8. the upregulation of others syncytial molecules, including LAG3, CTLA4, CD28 and CD3, assisting the formation of syncytia with APC cells. PMID: 27108398
    9. LAG3-expressing CD4(+)CD25(-) T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity. PMID: 28935468
    10. Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis PMID: 28800255
    11. Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8(+) TIL. PMID: 28115575
    12. our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors. PMID: 27912781
    13. this review provides the translational rationale for targeting LAG3, as well as historical and current state of clinical trials utilizing LAG3 cancer immunomodulators PMID: 28258692
    14. this study shows that LAG3 expressed on myeloid leukaemia cells possess the capacity to facilitate functional exhaustion in T helper cells PMID: 27565576
    15. epigenetic modification on LAG-3 increased LAG-3(+) T cells and its immune regulatory roles in chronic osteomyelitis progression PMID: 28028751
    16. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. PMID: 28349816
    17. LAG3 binds alpha-synuclein preformed fibrils (PFF) with high affinity (dissociation constant = 77 nanomolar), whereas the alpha-syn monomer exhibited minimal binding. alpha-Syn-biotin PFF binding to LAG3 initiated alpha-syn PFF endocytosis, transmission, and toxicity. PMID: 27708076
    18. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. PMID: 26013006
    19. LAG-3 is highly expressed in peripheral blood CD8+ T cells in chronic HBV-infected patients. PMID: 27053622
    20. iNKT cytokine production is profoundly altered by both HIV infection and treatment, and LAG-3, but not PD-1, expression is associated with a reduction in iNKT IFNgamma production. PMID: 25810006
    21. NFKB1, CD27, LAG3 and IKZF3 are new susceptibility genes for psoriasis. PMID: 25006012
    22. The elevated expression of LAG-3 at the genital tract suggests it may regulate T-cell activation, and identify cells susceptible to HIV infection. The enrichment of LAG-3 on double negative T cells suggests LAG-3 may contribute to the immunoregulatory activity of these cells. PMID: 25154740
    23. the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses. PMID: 25780040
    24. LAG-3 trafficking from lysosomal compartments to the cell surface is dependent on the cytoplasmic domain through protein kinase C signaling in activated T cells. PMID: 25108024
    25. These results suggest that LAG-3-mediated activation of plasmacytoid dendritic cells takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment. PMID: 24441096
    26. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. PMID: 23261718
    27. our data suggest that the LAG-3-MHC II interaction could be viewed as a bidirectional immune escape pathway in melanoma PMID: 21441454
    28. Multiple myeloma was associated with 2 SNPs in intron regions of LAG3 within 20 k base pairs 5' upstream of the candidate CD4 gene. The variant in LAG3 gene itself may play a role in susceptibility of MM. PMID: 20568250
    29. Analysis identified a gene-set (LAG3, LPL, ZAP70) whose overexpression is assigned to unmutated immunoglobulin variable heavy chain region with 90% specificity. PMID: 20228263
    30. LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer PMID: 20421648
    31. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. PMID: 20385810
    32. MHC class II-mediated signals induced by the natural ligand, LAG-3, lead to complete maturation of monocyte-derived dendritic cells, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses. PMID: 11937541
    33. LAG-3 induces rapid protein phosphorylation of phospholipase Cgamma2 and p72syk as well as activation of phosphatidyl inositol 3-kinase/Akt, p42/44 extracellular signal-regulated protein kinase, and p38 mitogen-activated protein kinase pathways. PMID: 12775570
    34. LAG3 may mediate sphingolipid metabolism PMID: 12825348
    35. LAG-3 activates antigen-presenting cells through MHC class II signalling, leading to increased antigen-specific T-cell responses in vivo. PMID: 14644131
    36. regulatory T cells and LAG-3 have pivotal roles in the suppression of EBV-specific cell-mediated immunity in Hodgkin lymphoma PMID: 16757686
    37. The result, including a total of 2640 MS patients and 2194 controls shows no significant association with CD4 and LAG3 and MS. We conclude that these genes are of minor importance in regard of genetic predisposition to the MS. PMID: 17020785
    38. Soluble human recombinant fusion protein (hLAG-3Ig) used in vitro as a single maturation agent induces phenotypic maturation of monocyte-derived dendritic cells and promotes the production of chemokines and TNF-alpha inflammatory cytokine. PMID: 18322184

    顯示更多

    收起更多

  • 亞細胞定位:
    [Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein.; [Secreted lymphocyte activation gene 3 protein]: Secreted.
  • 組織特異性:
    Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.
  • 數據庫鏈接:

    HGNC: 6476

    OMIM: 153337

    KEGG: hsa:3902

    STRING: 9606.ENSP00000203629

    UniGene: Hs.409523



主站蜘蛛池模板: 香蕉久久国产av一区二区| 688欧美人禽杂交狂配 | 国产一区二区三区自产| 美国一区二区三区无码视频| 中文成人无字幕乱码精品区| 成在人线av无码免观看午夜网 | 日韩精品射精管理在线观看| 国产999精品久久久久久| 成年午夜性影院免费观看| 亚洲中文字幕无码卡通动漫野外| 国产精品白浆无码流出视频| 亚洲精品日本久久一区二区三区| 亚洲毛片不卡av在线播放一区| 中文字幕丰满伦子无码| 亚洲性夜色噜噜噜在线观看不卡| 亚洲国产av美女网站| 国产成人精品高清在线观看99| 久久久久久人妻毛片a片| 亚洲精品色情app在线下载观看| 日韩 欧美 动漫 国产 制服| 欧美丰满一区二区免费视频 | 国产无套水多在线观看| 国产成人精品自在线拍| 国产成人无码a区视频在线观看 | 国产精品伦一区二区三级视频| 亚洲中文无码a∨在线观看| 综合精品欧美日韩国产在线| 性高朝久久久久久久久久| 日韩人妻一区二区三区免费| 宅男66lu国产在线观看| 久久精品国产久精国产爱| 欧美巨大巨粗黑人性aaaaaa| 国产精品熟妇视频国产偷人| 成年轻人电影免费无码 | 亚洲日韩中文第一精品| 日本熟妇色一本在线观看| 丰满的少妇hd高清中文字幕| 成在线人永久免费视频播放| 国产色视频自在线观看| 亚洲日韩看片无码超清| 一本大道东京热无码|